Burling Wealth Partners LLC Trims Position in Danaher Corporation $DHR

Burling Wealth Partners LLC lowered its position in Danaher Corporation (NYSE:DHR) by 4.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 24,711 shares of the conglomerate’s stock after selling 1,138 shares during the period. Burling Wealth Partners LLC’s holdings in Danaher were worth $4,881,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in DHR. Nuveen LLC bought a new position in Danaher in the 1st quarter worth approximately $833,941,000. Generation Investment Management LLP grew its position in shares of Danaher by 56.2% during the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after purchasing an additional 1,787,522 shares in the last quarter. Invesco Ltd. boosted its position in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after acquiring an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. lifted its position in Danaher by 290.6% during the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after purchasing an additional 1,072,617 shares during the last quarter. Finally, Parnassus Investments LLC increased its stake in Danaher by 23.3% during the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock worth $784,745,000 after acquiring an additional 722,636 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 29,728 shares of company stock valued at $6,448,990 in the last ninety days. Company insiders own 11.20% of the company’s stock.

Danaher Price Performance

DHR opened at $221.50 on Friday. The firm has a market capitalization of $156.46 billion, a PE ratio of 45.67, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The business’s 50-day moving average is $205.21 and its two-hundred day moving average is $200.91. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the company earned $1.71 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s payout ratio is presently 26.39%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. TD Cowen lifted their target price on Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Guggenheim reiterated a “buy” rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a report on Wednesday, October 8th. JPMorgan Chase & Co. increased their price objective on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Finally, Rothschild & Co Redburn reiterated a “neutral” rating and issued a $220.00 price target (down from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.